A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
David Ahern(University of Oxford), Hal Drakesmith(MRC Weatherall Institute of Molecular Medicine), Fabiola Curion(Helmholtz Zentrum München), Brian Angus(University of Oxford), Simon Davis, Tihana Bicanic(St George's, University of London), James Docker, Julie Dequaire, Andrew Brent(University of London), Alice Allcock, Sally Beer, Zhichao Ai, Eleanor Barnes(Oxford Health NHS Foundation Trust), J. Kenneth Baillie(NHS Lothian), Elizabeth Clutterbuck(University of Oxford), Rachael Bashford-Rogers(University of Cambridge), Emma E. Davenport(Wellcome Sanger Institute), Calliope A. Dendrou(University of Oxford), Andrew Brown, Neil Davidson, Lea Dib(Nuffield Orthopaedic Centre), Christina Dold(University of Oxford), Damien J. Downes(John Radcliffe Hospital), Paul Bowness(Broad Institute), Adam P. Cribbs(Centre for Human Genetics), Mark Coles(University of Oxford), Chris Allan, Moustafa Attar(Centre for Human Genetics), Dominik Aschenbrenner(John Radcliffe Hospital), Sagida Bibi(University of Oxford), Amanda Y. Chong(Centre for Human Genetics), Richard J. Cornall(John Radcliffe Hospital), Tao Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Ivan Candido-Ferreira, Amy Beveridge, M. Azim Ansari(Centre for Human Genetics), Archana Bashyal, Helen M. Byrne(University of Oxford), Carolina V. Arancibia-Cárcamo, Katie L. Burnham(Centre for Human Genetics), John Broxholme(Centre for Human Genetics), Mark Ainsworth(John Brown University), Wentao Chen, Yi‐Ling Chen(National Taiwan University), Christopher P. Conlon(Oxford Health NHS Foundation Trust), Philip D. Charles(University of Oxford), Luke Blackwell, G. Berridge, Susana Camara, David Buck(University of Oxford)
Cited by 327
Related Papers
An atlas of active enhancers across human cell types and tissues
|Nature|2014|2.8k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Global distribution and prevalence of hepatitis C virus genotypes
|Hepatology|2014|1.6k